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Background: Metformin is the first line of oral antidiabetic drug in the biguanide class for treatment of type 2
diabetes. Increasing evidence has suggested that it is a potential anti-tumor drug. However, the mechanisms
underlying inhibiting tumor development remain elusive, especially in bladder tumors.
Methods: T24 and J82 cell lines were used as an in vitro model, and 24 female SD rats were used to build an
N-methyl-N-nitrosourea (MNU)-induced orthotopic rat bladder cancer model. Transfection of lentivirus-based shRNA
was used to construct the STAT3-KNOCKDOWN T24 cell line. After metformin treatment, the viability of bladde
cancer cells was determined by CCK8. Cell cycle distribution and apoptosis were assessed by flow cytometry. The
migration and invasion abilities of cells were evaluated by wound healing and transwell asssays. The inactivation of
stat3 pahtway was examined by qRTPCR, western blot and Immunofluorescence.
Results: Metformin can effectively inhibit precancerous progression to invasive cancer in an MNU-induced rat
orthotopic bladder tumor model, although it could not completely suppress normal cells transforming into tumor
cells. While the MNU could induce 50 % rats (4/8) to develop invasive bladder cancers, the rats co-administrated
with metformin failed to develop invasive tumors but retained at precancerous or non-invasive stages, exhibiting as
dysplasia, papillary tumor and/or carcinoma in situ (CIS). Accordingly, phosphorylation of signal transducer and
activator of transcription 3 (STAT3), which is a well known oncogene, was significantly inhibited in the tumors of
rats treated with metformin. In vitro experiments revealed that the metformin could efficiently inhibit STAT3
activation, which was associated with the cell cycle arrest, reduction of cell proliferation, migration and invasiveness,
and increase in apoptotic cell death of bladder cancer cell lines.
Conclusions: These findings provide for the first time the evidence that metformin can block precancerous lesions
progressing to invasive tumors through inhibiting the activation of STAT3 pathway, and may be used for treatment
of the non-invasive bladder cancers to prevent them from progression to invasive tumors.
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Bladder cancer is the most common malignancy of the
urinary tract, ranking the 7th most common cancer in
men and the 17th in women [1]. At initial diagnosis,
nearly 75–80 % of cases are Non-Muscle-Invasive Bladder
Cancer (NMIBC, pTa-pT1), with the remaining Muscle-
Invasive Bladder Cancer (MIBC) [2]. The standard therapy
for NMIBC is Transurethral Resection of Bladder Tumor
(TURBT) combined with subsequent intravesical therapy,
with a high 5-year survival rates [2]. However, the five-
year recurrence and progression rates can add up to
31–78 % and 1–45 % respectively after the first treat-
ment [3, 4]. Therefore, finding an effective way of pre-
venting NMIBC progression and recurrence is required
urgently.
Metformin, 1, 1-Dimethylbiguanide hydrochloride, is
one of the most popular drugs which are used for type 2
diabetes therapy. It works by targeting the enzyme AMP
activated protein kinase (AMPK), which is regulated by
a protein kinase known as Liver Kinase B1 (LKB1), and
inducing muscles to take up glucose from the blood [5].
The LKB1 is a well recognized tumor suppressor and
can be activated by exercise, suggesting that metformin
might participate in suppressing tumorigenesis [6]. A
growing body of epidemiological investigation and pre-
clinical studies has shown that metformin treatment is
associated with reduced risk and better prognosis of
various types of cancers [6–8]. Interestingly, some recent
retrospective studies have demonstrated that metformin
could exert protective effects on recurrence in NMIBC
patients and cancer-specific mortality in MIBC patients
treated with radical cystectomy [9, 10]. However, the ef-
fects of metformin on bladder cancer have not been ad-
equately investigated and, in particular, the mechanisms
underlying the metformin inhibiting bladder cancer re-
main to be elucidated.
Signal transducer and activator of transcription 3
(STAT3) is a cytoplasmic transcription factor that can be
activated by tyrosine phosphorylation at position 705,
causing its dimerization, nuclear translocation, DNA bind-
ing, and activation of gene transcription [11]. It is known
that STAT3 is abnormally activated in many cancers and
plays an important role in tumor proliferation and metas-
tasis. It regulates cellular proliferation, invasion, migration,
and angiogenesis [11, 12]. Moreover, it has been reported
that activation of STAT3 is crucial for bladder cancer car-
cinogenesis, growth, survival and progression in vitro and
in vivo [13, 14]. STAT3 has been considered as a promis-
ing molecular target for cancer therapy.
The purpose of this study is to evaluate the effects of
metformin on bladder cancer using an in vitro model of
human urinary bladder-cancer and an in vivo model of rat
orthotopic bladder cancer and explore the role of metfor-
min in regulating STAT3 pathway.Materials and methods
Cell lines, medium and cell culture
Human bladder cancer cell lines T24 and J82 were pur-
chased from the American Type Culture Collection
(ATCC, Rockville, MD, USA) and were cultured in 10 %
fetal bovine serum (Invitrogen) Dulbecco’s Modified
Eagle’s Medium (DMEM) (Invitrogen, Carlsbad, CA,
USA)) supplemented with penicillin (100 units/ml) and
streptomycin (100 μg/ml). Cells were incubated at 37 °C
with 5 % CO2.
Construction of STAT3-KD Cell Line
To construct a stable STAT3-KNOCKDOWN cell line,
we transfected T24 cells with lentivirus-based shRNA
vector (purchased from GenePharma, Shanghai, China).
The shRNA oligonucleotides sequences targeting STAT3
and acting as normal control are as follows: GCGTCC
AGTTCACTACTAAAG; TTCTCCGAACGTGTCACGT.
Transfections were performed with polybrene (Gene-
Pharma) according to manufacturer’s instruction. Stable
clones were selected in 1000 μg/ml neomycin (Invitrogen)
for 2 months.
Cell viability assay
Cell viability assays were performed with a Cell Counting
Kit-8 (Dojindo, Kumamoto, Japan). Cells were seeded in
96-well plates in triplicate (5 × 103 per well) for 24 h. Then
the medium was removed and replaced by fresh culture
medium containing metformin (Sigma-Aldrich, St. Louis,
MO, USA) in various concentrations (0, 10, 20, 40 or
60 mM) for 24 or 48 h. The number of viable cells per
well was measured by the absorbance (450 nm) of reduced
2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2, 4-
isulfophenyl)-2H-tetrazolium (monosodium salt) using
the Microplate Autoreader (Bio-Tek Instruments Inc.,
Winooski, VT, USA). Independent experiments were
repeated for three times.
Analysis of cell cycle and apoptosis
Cell apoptosis detection kit (propidium iodide (PI),
RNase staining buffer and FITC-labeled Annexin V)
were purchased from BD Pharmingen (San Diego, CA,
USA). Cells were seeded 2.5 × 105 per well in 6-well
plates for 24 h. Then the medium was replaced by cul-
ture medium containing metformin 0, 20 or 40 mM for
24 or 48 h. The cells were harvested for analysis of cell
cycle and apoptosis, respectively. The cell cycle was ana-
lyzed using PI staining, according to the manufacturer’s
instructions. Briefly the cells were fixed in 70 % ethanol,
stained with PI, and the amount of PI-labeled DNA in a
cell was measured by a flow cytometer (Accuri C6, Becton
Dickinson, San Jose, CA, USA). The acquired data
were analyzed by FlowJo software (Ashland, OR, USA).
To determine the apoptotic cells, the cells were stained
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vesting, and analyzed by flow cytometry, as described
by the manufacturer’s instructions.Wound healing assay
T24 cells were seeded 5 × 105 per well in 6-well plates
and cultured until they reached complete confluence.
Cells were scratched with a pipette tip and washed with
PBS buffer. Then cells were cultured in 1 % FBS DMEM
containing metformin (0, 10 or 20 mM). Photographs
were taken in pre-marked spots at 0, 12 and 24 h of cul-
ture for comparison. The number of cells migrated into
the wound areas was counted.Transwell assay
T24 cells were treated with metformin (0, 10 or20 mM)
for 24 h. Then cells were seeded 3 × 104 cells per well in
150 μl 1 % FBS DMEM supplemented with 0, 10 or
20 mM metformin into the upper chamber of the trans-
well in 24-well plates (growth surface area of insert:
0.33 cm2; membrane pore size, 8 μm; Corning Incorpo-
rated; Corning, NY, USA) with or without Matrigel (BD
Pharmingen), and 500 μl 10 % FBS DMEM was added
into the lower chamber. After 24 h, the bottom of the
inserts were fixed in methanol for 10 min and stained
with 0.1 % crystal violet staining solution. The cells mi-
grating or invading into the bottom-lower surfaces of in-
serts were measured by using an inverted phase contrast
microscope.Western blot analysis
The cells and tissues were collected and lysed in Radio-
Immunoprecipitation Assay (RIPA) buffer (Thermo
Fisher, Rockford, IL, USA) containing 1 % phenylmethyl-
sulfonyl fluoride (PMSF). Protein concentration was
quantified with the BCA Protein Kit (Beyotime, China).
Lysates (30 μg protein) were separated by 10 % SDS-
PAGE gels electrophoresis and transferred to a PVDF
membrane (Bio-Rad, Hercules, CA, USA). The mem-
branes were blocked in TBS/Tween20 (TBST) buffer
containing 5 % non-fat milk powder for 2 h at room
temperature, and then probed with primary antibodies
overnight at 4 °C. Rat monoclonal antibodies (mAbs) to
pstat3 (Y705), stat3, cyclin D1, Bcl-XL, Bcl2 and β-actin
were purchased from Cell Signaling (Beverly, MA, USA),
horseradish peroxidase (HRP)-conjugated anti-rabbit
IgG antibody was purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). After incubated with sec-
ondary antibodies for 1 h at room temperature, protein
signal was detected with the ECL chemiluminescent de-
tection system (Bio-Rad), and protein levels were nor-
malized to β-actin.Immunofluorescent microscopic analysis
For cytochemical analysis of phosphorylated STAT3
(pstat3), cells cultured in 96-well plates were fixed and
permeablized in methanol for 30 min followed by block-
age in 5 % bovine serum albumin (BSA) for a another
30 min and then incubated with primary antibody over-
night at 4 °C. The cells were washed 3 times with Tris-
Buffer Solution Tween (TBST) and then incubated for
1 h with FITC-conjugated anti-rabbit IgG secondary
antibody (BD Pharmingen) at room temperature. Nuclei
were stained with Hoechst 33342 (10 μg/ml; Sigma-
Aldrich) for 3 min. Samples were examined and micro-
photographed under a fluorescent microscope (Nikon
Instruments Inc. Melville, USA).
Real-time PCR analysis
Total RNA was extracted from human bladder cancer
cells using Trizol (Invitrogen). The cDNA was synthesized
from 0.5 μg of RNA with a Prime Script Kit (TAKARA,
Toyobo, Osaka, Japan). Gene transcription levels were
quantified by real-time quantitative PCR with SYBR Green
PCR real-time PCR Master Mix (TAKARA). β-actin was
used as an endogenous control. All the samples were de-
tected in triplicate for each experiment. All results shown
were representatives of three independent experiments,
and mRNA levels were expressed as 2-ΔΔCT. The PCR
were performed with a two-step qRT-PCR at 95 °C for
10 min, then 40 cycles of 95 °C for 15 s and 60 °C for
1 min, followed by 95 °C for 15 s. The specific primers
used were listed as follows:
β-actin forward: CATGTACGTTGCTATCCAGGC,
reverse: CTCCTTAATGTCACGCACGAT,




cyclin D1 forward: GCTGCGAAGTGGAAACCATC,
reverse: CCTCCTTCTGCACACATTTGAA.
Establishment of orthotopic rat bladder cancer model
Twenty-four female SD rats weighting around 280 g
were obtained from the Experimental Animal Center of
Renji Hospital, School of Medicine, Shanghai Jiaotong
University (Shanghai, China) and housed in the center.
Animal protocols in the study were approved by the
Institutional Animal Care and Use Committee of Renji
Hospital, School of Medicine, Shanghai Jiaotong University.
They were maintained in an air-conditioned room lighted
12 h every day , given standard laboratory rat chow and
could freely access to tap water. All rats were acclimatized
for 7 days before the experiments started. The rats were
divided into three groups (Additional file 1: Figure S1):
a control group (n = 8); an N-methyl-N-nitrosourea
Fig. 1 (See legend on next page.)
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Fig. 1 Metformin inhibited the proliferation, cell cycling and viability of bladder cancer cells. a Inhibition of cell proliferation: J82 and T24 cells
were seeded 5 × 103 per well in 96-well plates for 24 h. Then cells were treated with metformin (0, 10, 20, 40, or 60 mM) for 24 or 48 h. Cell
numbers and viability was evaluated by CCK8. b Cell cycle arrested at G0/G1 phases: J82 and T24 cells were treated with 20 mM metformin for 24
or 48 h and cell cycle were analyzed by flow cytometry. c Promotion of apoptotic cell death: J82 and T24 cells were treated with 20 and 40 mM
metformin for 24 or 48 h, stained with PI and FITC-labelled Annexin V and determined by flow cytometry for the frequency of apoptotic cells.
Top panel: representative histograms of cell cycling; bottom panel: summary of apoptotic cells (%) from three reproducible experiments.
**, P < 0.01 when compared to control group (0 mM) in all the experiments
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of rats cotreated with MNU and metformin (Met group)
(n = 8). Briefly, the rats were anesthetized i.p. with Nem-
butal (50 mg/kg). Two mg of MNU (Sigma-Aldrich)
that was dissolved in sodium citrate buffer (10 mg/ml)
was administered to the rats of the MNU group and the
Met group via rat epidural catheter intravesically within
30 min of preparation of MNU solution every other
week (weeks 0, 2, 4 and 6) for a total 4 doses. The rats
remained anesthetized for approximately 2 h after
catheterization. Rats of the Met group were adminis-
tered with metformin (2 g/L) in the drinking water. All
the rats were monitored for 14-weeks. Body weight
(BW) was measured every two weeks and drinking
water was replaced twice a week during the experimen-
tal period.
At the end of the experiment, all the rats were sacri-
ficed by intraperitoneal administration of an overdose of
Nembutal. The lungs, stomach, liver, kidneys, uteruses
and intestines were harvested and evaluated for meta-
static lesions. Before removal, bladders were fixed by
intravesically injecting 1 ml buffered formaldehyde solu-
tion. After overnight pre-fixation, each bladder was cut
open, and its mucosal surface was macroscopically eval-
uated for urothelium lesions. Then the bladder tissues
were processed for paraffin-embedding and sectioning.
The paraffin-embedded tissues were sectioned in a 2 μm
thickness, mounted in slides and stained with haema-
toxylin & eosin (H&E). The slides were randomized and
carefully examined histologically by two pathologists
indepently. Histologic lesions were classified and staged
according to the World Health Organization/Inter-
national Society of Urological Pathology Consensus
Classification of Urothelial (Transitional Cell) Neo-
plasms of the Urinary Bladder.
Statistical analysis
All data were presented as means ± S.D. All statistical
analysis was performed with GraphPad Prism version
5.00 software from GraphPad Software (San Diego, CA,
USA). For in vitro studies, comparison between control
group and metformin-treated group was performed by
using Student’s t-test. For in vivo studies, difference be-
tween tumor areas was assessed by Student’s t-test, andhistopathological examination was evaluated by Chi-square
test. The P-value of < 0.05 was considered statistically
significant, p < 0.01 was considered statistically highly
significant.
Result
Metformin inhibits the proliferation and expansion of
bladder cancer cells by inducing cell cycle arrest and
apoptosis, respectively
To evaluate the effects of metformin on human bladder
cancer cell lines, we treated two bladder cancer cell
lines, J82 and T24, with metformin. Both cell lines were
seeded in 96-well plates and cultured in the presence of
metformin at variable concentrations (0, 10, 20, 40 or
60 mM) for 24 and 48 h. Then cell viability was deter-
mined by CCK8 assay. Metformin is capable of inhibit-
ing the growth of both J82 and T24 cell lines in a
dose—and time-dependent manner, as shown in Fig. 1a.
To determine the underlying mechanism, we further in-
vestigated the effect of metformin on the cell cycling of
the bladder cancer cells by flow cytometry. Treatment of
J82 and T24 cells with 20 mM metformin for either 12
or 24 h arrested cell cycle at the G0/G1 phase. As shown
in Fig. 1b, a significantly increased proportion of cells
was observed arrested at the G0/G1 phase, while the per-
centage of cells in the S phase sharply decreased accom-
panied by a drop in the percentage of cells at the G2/M
phase. Whether metformin can induce apoptosis in blad-
der cancer cells was also determined by flow cytometry.
We treated both cell lines (J82 and T24) with 0, 20 or
40 mM metformin for 24 and 48 h and then analyzed
their apoptosis by flow cytometry. The result showed
that metformin induced an increase in the percentage of
apoptotic cells in both cell lines in a dose—and time-
dependent manner (Fig. 1c). These results demonstrate
that metformin inhibits the proliferation of bladder can-
cer cell lines by blocking cell cycle progression at the
G0/G1 phase and cell expansion by inducing apoptotic
cell death.
Metformin suppresses bladder cancer cell migration and
invasion in vitro
T24 cell line was derived from an invasive high-grade
urothelial carcinoma [15], and so we selected T24 to
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gration and invasion of bladder cancer with the wound
healing assay as well as transwell assay. We treated T24
cells with 10 or 20 mM metformin, and compared the
number of migrated or invaded cells with control
groups. As shown in Fig. 2a, metformin significantly
suppressed T24 cell migration to the wound area and
the highest inhibitory effect was observed at 24 h in the
wound healing assay. Consistently, the migration and in-
vasion of T24 cells were also dramatically inhibited by
metformin at 24 h of Transwell assay (Fig. 2b). Taken to-
gether, these results suggest that metformin can suppress
the capability of bladder cancer cells to migrate and in-
vade in vitro.
Metformin can inhibit precancerous progression of rat
bladder tumor
Because metformin was observed to inhibit proliferation,
viability, migration and invasion of bladder cancer cells
in vitro, we next explored whether it had inhibitory ef-
fects on bladder carcinogenesis, using the MNU-induced
orthotopic rat bladder cancer model. All rats were
randomly divided into three groups (Additional file 1:
Figure S1), including a control group, a MNU-induced
group (MNU group) and a group of rats co-treated with
MNU and metformin (Met group). All rats were sur-
vived at the end of the experiment and no significant
difference in the body weight and diet consumption was
observed among the three groups (data not shown).
Macroscopical examination showed no neoplasmicFig. 2 Metformin inhibited migration and invasion of bladder cancer cells.
migration and invasion were assessed by wound healing assay (a) and tran
invasion assays are shown in left panel and quantitative results are shown
independent experiments. **, P < 0.01 when compared to control groups. Slesions in the urothelial texture of bladders from the
control group (0 %), but large neoplasmic lesions in the
bladders from MNU-induced group (100 %; 8/8) and,
interestingly, reduced neoplasmic lesions in frequency and
size in the Met group (87.5 %; 7/8). The mean tumor sur-
face areas per rat in the MNU group (48.84 ± 17.82; mm2;
n = 8) was two times more (P < 0.05) than in the Met
group (17.5 ± 10.88 mm2; n = 7), indicating a significant
reduction of tumor growth in Met group (P < 0.05)
(Fig. 3a-c & Table 1).
Histological examination further revealed that while
various types of neoplastic lesions including precancer-
ous and invasive ones occurred in the MNU-induced
group, no invasive lesions were observed in the Met
group (Fig. 3d-h & Table 1). As shown in Table 1, Met
group developed significantly less cases of carcinoma in
situ (CIS) (37.5 % vs 75 %, P < 0.05) and infiltrative (inva-
sive) tumors (0 % vs 50 %, P < 0.05) than MNU group.
At the time of sacrifice, precancerous lesions such as
dysplasia were only observed in Met group, which had
developed into CIS or infiltrative tumors in MNU group.
Interestingly, four rat bladders from the Met group de-
veloped alone with papillary tumors, which always coex-
isted with CIS in the MNU group. CIS in the bladder is
considered as an early stage of cancer with invasive po-
tential, whereas papillary tumor is non-invasive with
limited invasive potentials. The results strongly sug-
gested that metformin was an efficient agent preventing
progression of precancerous lesions to invasive tumors
in the MNU-induced rat bladder cancers.T24 cells were treated with metformin for 24 h, and the capacity of
swell migration assays (b). Representative pictures of migration and
in right panels. The data presented are expressed as mean ± SD from 3
cale bars in the micrographs represent 100 μm
Fig. 3 Macroscopic and microscopic examinations of tumors in MNU-induced and metformin-treated rat bladders. Macroscopic graphs (A-C):
a Bladders from the control group showed a normal appearance; b Bladders from the MNU-induced group had thicker walls and a wider range
of tumor lesions (outlined by the dotted line); c Bladders from the metformin-treated group showed some tiny and isolated lesions (indicated by
the arrow). Histopathological examinations (D-H): tissue or tumor sections were stained with H & E and analyzed by pathologists double blindly.
d Normal uroepithelial cells were observed in the control group; e Low grade and f high grade papillary tumor were found mainly in the
metformin-treated group, and (g) CIS and (h) Infiltrative (invasive) tumors were found mainly in the MNU group. No invasive tumors were
observed in Met group. i Summary of tumor sizes in the MNU group and Met group. **, P < 0.01 when compared to MNU group. Magnificaiton
of micrographs: x100
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inhibiting STAT3-mediated signaling pathways
It has been reported that STAT3 activation in urothelial
basal cells results in progression of CIS to invasive can-
cer in an orthotopic mouse bladder cancer model [13].
Therefore, we investigated whether metformin suppress-
ing progression of precancerous lesions to invasive
cancers in the MUN-induced rat bladder cancer model
was associated with inhibition of STAT3 activation.
We harvested “normal” urothelial cells from control
group and tumor tissues from the MUN and Met
groups for Western blot analysis. The results showedthat STAT3 phosphorylation was significantly activated
in tumor tissues compared with normal urothelial
cells. However, the activation was remarkably weak-
ened in Met group, compared to MNU group (Fig. 4a),
suggesting that metformin blocked progression of
MNU-induced precancerous lesions to invasive ones
through inhibiting STAT3 phosphorylation.
To confirm the finding, we next treated T24 and J82
cell lines with metformin and evaluated its effect on acti-
vation of STAT3 signaling pathways by western blotting
and immunofluorescent microscopy. As shown in Fig. 4b
and d, phosphorylated STAT3 was constitutively detected
Table 1 The effects of metformin on the development of MNU-induced rat orthotopic bladder tumors
Macroscopy & microscopy Control (n = 8) MNU (n = 8) MNU +Met (n = 8) P value
Frequency of tumoringenivity [%(n/n)] 0 100(8/8) 87.5(7/8) 0.5
Areas of tumors [mm2(n)] 0 48.84 ± 17.82(in 8) 17.5 ± 10.88(in 7) 0.0014
Preneoplasic lesions[%(n/n)]
Hyperplasia 0 0 0 1
Dysplasia 0 0 12.5(1/8) 0.302
Neoplasic lesions[%n/n]
Papillary tumor 0 37.5(3/8) 75(6/8) 0.046
Carcinoma in situ 0 75(6/8) 37.5(3/8) 0.046
Infiltrative tumor 0 50(4/8) 0 0.021
Accompanied other pathology [%(n/n)]
Squamous differentiation 0 37.5(3/8) 12.5(1/8) 0.248
Sarcoma 0 12.5(1/8) 0 0.302
P values represent comparion between MNU group and Met group
Note: Multiple lesions at various stages were detected in the same bladders of MNU-induced rats, including papillary tumors, CIS, infiltrative tumors and sarcomas.
Upon treatment with metformin, MNU-induced rats were only detected with dysplasia, papillary tumors and CIS. Tumor incidence and tumor size (areas) in
MNU-induced rats were reduced upon treatment with metformin
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without treatment with metformin. The level of phosphor-
ylated STAT3 was remarkably decreased after treatment
with metformin in dose—and time-dependent manners.
Because STAT3 is a classical cancer-related transcription
factor and regulates a range of downstream target genes
such as cyclin D1, Bcl-XL and Bcl2 that play important
roles in cell cycle and cell survival [11], we analyzed the
expression of these genes at the levels of mRNA and pro-
tein in the cells treated with or without metformin. Upon
the treatment with 20 mM metformin for 24 h, cyclin
D1, Bcl-XL and Bcl2 were decreased significantly in
both transcriptional (mRNA) and translational (protein)
levels (Fig. 4c).
Next we constructed the STAT3-KNOCKDOWN T24
cell line (T24/STAT3-KD) and the normal control cell
line (T24/control) to compare the metformin sensitivity
between STAT3 inactivated and activated bladder cancer
cells (Fig. 4e). Under normal culture conditions, T24/
STAT3-KD cells proliferated less rapidly than T24/con-
trol cells (data not shown). As shown in Fig. 4f, metfor-
min treatment for 48 h could suppress the proliferation
of both cell lines, however, the cell viablity of T24/control
cells was inhibited much more significantly than T24/
STAT3-KD cells (P < 0.01). Then we evaluated the in-
hibitory effects on migration and invasion abilities of
both cell lines after 5 mM metformin treatment. Nor-
mally T24/STAT3-KD cells had weakened migration
and invasion abilities, compared with T24/control cells.
Interestingly, metformin treatment was capable of de-
creasing T24/control cells by 237.7 ± 22.7 and 119.7 ± 6.8,
in migration and invasion assays respectively. By constrast,
such an inhibitory effect attenuated significantly in
T24/STAT3-KD cells as migrating and invading cells werereduced by only 131.7 ± 19.8 (P < 0.01) and 87.7 ± 15.2
(P = 0.029), respectively (Fig. 4g).
Taken together, STAT3 played an important role for
precancerous progression to invasive ones, metformin
could efficiently inactivate STAT3, and as a result, tran-
scription of its target genes was inhibited, leading to
suppression of tumor development or tumorigenesis.
Discussion
This study explored the anti-tumor effects of metformin
on bladder cancer using both in vitro and in vivo models
of human bladder cancers. We have found that metfor-
min play an important role in blocking progression of
precancerous lesions to invasive cancer in bladder, and
this effect is mediated by inhibiting STAT3 phosphoryl-
ation, which leads to suppress a number of target genes
of STAT3, such as cyclin D1, Bcl-XL and Bcl2. Therefore,
metformin blocks the precancerous progression through
inhibiting STAT3-mediated signal pathways involved in
cell survival, proliferation, migration and invasion.
As an inexpensive and effective oral drug, metformin
has been applied for the treatment of type 2 diabetes for
decades. Its potential mechanisms are to promote glu-
cose uptake and increase fatty acid oxidation in muscle
and liver without obvious adverse effects [5, 16]. Al-
though the value of metformin has been investigated in
clinical trials for many types of cancers [6–8], including
two recent retrospective studies on bladder cancer [9,
10], its specific effects on bladder cancers such as prolif-
eration, viability, migration and invasion have not been
adequately investigated in vitro and in vivo. Although a
recent study demonstrated that metformin could inhibit
the proliferation of bladder cancer cell lines and the
growth of bladder cancer in a xenograft model [17], our
Fig. 4 (See legend on next page.)
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Fig. 4 Metformin inactivated stat3-mediated signaling pathways in bladder cancer cells in vivo and in vitro. a-b The expression of STAT3 and
pstat3 in vivo and in vitro with or without treatment with metformin were examined by western blot. c The expression of transcripts (top panel)
and proteins (bottom panel) of STAT3 targeting genes in bladder cancer cell lines treated with or without metformin, including cyclinD1, Bcl-XL
and Bcl2. Top panel: the transcripts assessed by qRT-PCR, bottom panel: the proteins detected by Western blot. d The expression and location of
pstat3 in bladder cancer cell lines treated with or without metformin were evaluated by immunofluorescent microscopy. Scale bar represents
25 μm. e Construction of the T24/STAT3-KD bladder cancer cell line with the relative low level of phospholyrated STAT3 compared with normal
control cell line T24/control. f T24/STAT3-KD and T24/control cells were treated with metformin (0, 10, 20, 40, or 60 mM) for 48 h. Cell viability
was evaluated by CCK8. g T24/STAT3-KD and T24/control cells were treated with metformin for 24 h, and the abilities of migration and invasion
were assessed by Transwell. Representative pictures of migration and invasion assays are shown in left panel and quantitative results are shown
in right panels. Scale bars in the micrographs represent 100 μm. All data presented are expressed as mean ± SD from 3 independent experiments.
**, P < 0.01; *, P < 0.05
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formin suppressing bladder cancer proliferation, expan-
sion, migration and invasion in vitro and in vivo.
Importantly, we have for the first time demonstrated
that metformin can prevent precancerous progression
through inhibiting STAT3-mediated signaling pathways
in a MNU-induced orthotopic rat bladder cancer model.
This finding is of significance in clinic practice for the
development of novel strategy for preventing progres-
sion of NMIBC to invasive cancers.
The underlying mechanisms how metformin inhibits
cancer cells remain to be further elucidated, while the
signaling pathways involved in cell proliferation, cell cyc-
ling and apoptotic cell death have been considered as
potential pathways [18–20]. In this study, treating two
bladder cancer cell lines T24 and J82, which were de-
rived, respectively, from MIBC and NMIBC, with met-
formin for 24 h and 48 h inevitably resulted in cell cycle
arrest and apoptotic cell death, consistently with the ob-
servations from other laboratories [18–20]. One recent
study demonstrated that metformin could arrest bladder
cancer cells in the G0/G1 phase with concomitant de-
creases in the expression of cyclin D1, CDK4 and E2F1
[17], which is verified again in our study. However, the
ability of metformin to induce apoptotic cell death
remained controversial. It has been showed that metfor-
min could block the cell cycle of prostate cancer cells at
the G0/G1 phase but did not induce apoptotic cell death
[21]. The discrepancy between studies may be associated
with variations in experimental conditions, tumor types
and diversity of cell lines.
The mechanisms of metformin anti-tumor effects are
considered to be associated with both indirect and direct
effects on cancer cells. Metformin not only lowers circu-
lating glucose concentration via an increase in muscle
glucose uptake and suppression of hepatic gluconeogen-
esis, but also circulating insulin levels [6, 8]. Previous
studies have shown that the type 1 insulin-like growth
factor receptor is over expressed in bladder cancer, and
high doses of human insulin and insulin glargine can
promote bladder cancer cell proliferation in vitro [22, 23].
These results suggest that metformin could indirectlyinhibit tumor development through decreasing glucose
and insulin in circulation. The direct effects of metformin
were firstly evaluated on breast cancer cells [24, 25], in
which AMPK was primarily activated and mammalian tar-
get of rapamycin (mTOR) signaling and protein synthesis
were subsequently reduced. Such mechanism may also
apply to bladder cancer cells [17]. In our study, metformin
directly inhibited the phosphorylation of STAT3, inactivat-
ing STAT3-mediated signaling pathways involved in cell
proliferation, viability, migration and invasion. When
STAT3 pathway was inactivated in T24/STAT3-KD cells,
these bladder cancer cells, like T24 cells treated with met-
formin, turned to the phenotypes of weakened prolifeara-
tion, migration and invasion abilities. Accordingly, unlike
T24/control cells with a high phosphorylated STAT3
levels, the inhibitory effects of metformin on T24/STAT3-
KD cells were significantly attenuated. In our experiments,
some of STAT3 classic target genes such as cyclin D1,
Bcl2, Bcl-XL were all significantly down regulated upon
metformin treatment. Cyclin D1 plays a vital role in pro-
moting cell cycle G1/S phases transition [26, 27], consist-
ently with our findings that the metformin-treated bladder
cancer cells were tended to be arrested at G0/G1 phase
and the number of S phase cells were greatly decreased.
Previous reports have shown that the cyclin D1 was con-
stitutively overexpressed in several human tumors includ-
ing bladder cancer [28]. Thus, the down regulation of
STAT3/cyclin D1 signaling can account for the cell cycle
arrest in the G0/G1 stage and reduced G1/S phase transi-
tion in the bladder cancer cells treated with metformin.
Moreover, Bcl2 and Bcl-XL, as pro-survival genes directly
transcripted by STAT3 [11], were also repressed by met-
formin, suggesting that down-regulaiton of STAT3/Bcl2/
Bcl-XL signaling pathways in metformin-treated bladder
cancer cells caused increased apoptotic cell death.
In additon, STAT3 directly binds to the promoter of
matrix metalloproteinase(MMP) 2 and upregulates its
expression. It may also regulates activity of other MMP
family members [29, 30], which were associated with
tumor invasion. STAT3 also regulates cellular migration
by modulating the activity of Rho and Rac [31, 32]. In an
orthotopic mouse bladder cancer model, STAT3-transgenic
Pan et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:77 Page 11 of 12mice, compared with the wild-type counterparts, developed
invasive cancer directly from carcinoma in situ (CIS) in a
shorter time, bypassing the noninvasive papillary tumor
stage [13]. These findings suggested that STAT3 is also a
key regulator for migration and invasion of cancer cells
and might play a master role in driving precancerous pro-
gression to invasive or malignant tumors. The hypothesis
is supported by our findings that metformin treatment
suppresses invasion and migration of bladder cancer cells
in vitro and blocks precancerous lesions and CIS progres-
sing to invasive cancers in orthotopic rat bladder cancer
model. In consistence with the phenomenon, STAT3
phosphorylation was remarkably inhibited by metformin
either in vitro or in vivo models of bladder cancers, ac-
companied by reduced capacity of migration and invasion
of cancer cells in vitro and arrested progression of precan-
cerous lesions. Moreover, the tumor developments in
MNU-induced rats were arrested at the papillary tumor
stage when treated with metformin. Therefore, we con-
clude that metformin can block precancerous progression
to invasive cancers through inhibiting STAT3-mediated
signaling pathways.
MNU-induced rat bladder cancer intimately mimicked
human bladder cancer. Six weeks of MNU intravesical
induction followed by 8 weeks of observation revealed
all the stages of bladder cancer in pathology: bladder
epithelial cells progressing from atypical hyperplasia to
flat CIS and transitional cell carcinoma [33]. In our
study, tumor incidence reached 100 %, consistently with
previous reports [33, 34], but not with other study, in
which the tumor incidence was much lower [35]. The
tumor incidence was slightly reduced in metformin-
treated group (87.5 %), suggesting metformin has the
potential to inhibit cell transformation induced by
MNU, but very limited. Essentially, metformin has little
ability to inhibit uroepithelial transformation, but could
almost completely block progression of preneoplasms or
non-invasive tumors, because no invasive cancer and
sarcoma was observed in metformin-treated rats and the
tumors in metformin-treated group were limited at the
stages of dysplasia, papillary tumor or CIS. Compared
with the xenograft model of bladder cancer [17], our
orthotopic rat bladder cancer model more realistically
imitated the developmental process of human bladder
cancer [33].
Moreover, feeding rats 2 g/L metformin solution
means that each rat was administrated metformin at ap-
proximate 200 mg/kg/day, which has been reported as
the no observable adverse effect level (NOAEL) in rats
[36]. Accordingly, such doses of metformin caused no
side-effect and body weight change in these rats (data
not shown). Considering the information that the max-
imum recommended daily dose of metformin for the
treatment of type 2 diabetic patients is 2550 mg/day andthe fact that 200 mg/kg/day in rats is equivalent to
1200 mg/60 kg/day in humans, our study suggested that
metformin could inhibit bladder cancer in vivo even at a
safe daily dose.
It has been considered that tumor development is me-
diated by tumor stem cells (TSCs) [37–39]. A TSC can
be initiated from a healthy cell that hierarchically de-
velops into tumor-initiating stem cell (TISC), precancer-
ous stem cell (pCSC) and then cancer stem cell (CSC) in
carcinogenic environments. The progenies of CSCs,
cancer-propagating progenitor cells (CPCs), are a major
population contributing to the formation of tumor mass
[40]. Although this novel model for TSC development
has attracted the attentions from colleagues, it remains
to be verified in animals and human. The MNU-induced
orthotopic rat bladder cancer model is suitable for verifi-
cation of the TSC model, and metformin may be used to
precisely dissect or demarcate between precancerous
and cancerous stages of a bladder TSC.
In summary, this study demonstrates that metformin
can block preneoplasm or non-invasive cancer of blad-
der progressing to invasive cancer through inhibiting
STAT3-mediated signaling pathways which can promote
viability, proliferation, migration and invasiveness of
cancer cells. Our results suggest that metformin could
be a potential candidate for the development of novel
therapeutic strategies for human bladder cancer.
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